Use of human serum albumin to decrease antigenicity of therapeutic proteins
AssigneeProtox Therapeutics, Inc.
InventorFahar Merchant
Life of this patent
Estimating the term…
Abstract
Provided herein are therapeutic compositions that include albumin (such as human serum albumin) and therapeutic proteins, such as a modified proaerolysin protein or an apoptosis-modulating fusion protein, as well as kits that include such compositions in containers. Also provided are methods of using such compositions in decreasing the antigenicity of therapeutic proteins such as modified proaerolysin proteins or apoptosis-modulating fusion protein antibodies (for example as evidenced by a decrease in the production of neutralizing antibodies).
Claims93
A pharmaceutical composition, comprising:
- albumin;
- and
- a modified proaerolysin protein, wherein the modified proaerolysin protein comprises a prostate-specific protease cleavage site that replaces a proaerolysin furin cleavage site corresponding to amino acids 427-432 of SEQ ID NO:
- 2.
A kit, comprising:
- a first container containing the therapeutic protein of SEQ ID NO:
- 28;
- and
- a second container containing human serum albumin.
A method of decreasing an antibody response to a therapeutic protein of selected from SEQ ID NO:
- 4 and SEQ ID NO:
- 28 comprising administering the therapeutic protein to the subject in a pharmaceutical composition comprising a sufficient amount of albumin to decrease the subject's antibody response to the therapeutic protein.
A method of decreasing an antibody response to a therapeutic protein in a subject in need of treatment therewith, comprising administering the therapeutic protein to the subject in a pharmaceutical composition comprising a sufficient amount of albumin to decrease the subject's antibody response to the therapeutic protein.
A pharmaceutical composition comprising:
- albumin;
- and
- a therapeutic protein selected from the group consisting of:
- an apoptosis-modifying fusion protein comprising an inactive toxin protein domain and an apoptosis regulating protein domain, wherein the inactive toxin protein domain targets the fusion protein to the cell and is not biologically active, or
- a targeted cargo protein, comprising a targeting moiety that specifically binds to a target displayed by a target cell, and a cargo moiety that exerts a biological effect on a target cell.
Dependencies are inferred from the claim text.